

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 July 2001 (19.07.2001)

(10) International Publication Number
PCT WO 01/51082 A1

(51) International Patent Classification: **A61K 39/39**,
39/395, 39/35, 39/00, 39/02, 39/12, 31/7088, C12N 15/63,
A61P 31/00, 35/00, 37/00

Wallace [US/US]; 516 South 6th Street, Hamilton, MT
59840 (US).

(21) International Application Number: PCT/GB01/00142

(74) Agent: **MALLALIEU, Catherine, Louise**; D. Young &
Co., 21 New Fetter Lane, London EC4A 1DA (GB).

(22) International Filing Date: 15 January 2001 (15.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0000891.2 14 January 2000 (14.01.2000) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicants (*for all designated States except US*): **AL-
LERGY THERAPEUTICS LIMITED** [GB/GB];
Dominion Way, Worthing, West Sussex BN14 8SA (GB).
CORIXA CORPORATION [US/US]; Suite 200, 1124
Columbia Street, Seattle, WA 98104 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **WHEELER, Alan**
[GB/GB]; Allergy Therapeutics Limited, Dominion Way,
Worthing, West Sussex BN14 8SA (GB). **ELLIOTT, Garry**
[US/US]; Corixa Corporation, 553 Old Corvallis
Road, Hamilton, MT 59840 (US). **CLUFF, Christopher**,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/51082 A1

(54) Title: COMPOSITION OF ANTIGEN AND GLYCOLIPID ADJUVANT SUBLINGUAL ADMINISTRATION

(57) Abstract: A method of producing a mucosal and systemic immune response in a mammal comprising administering sublingually an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said mammal.

COMPOSITION OF ANTIGEN AND GLYCOLIPID ADJUVANT SUBLINGUAL ADMINISTRATION

Field of the Invention

- 5 The present invention relates to a method of producing a mucosal and systemic immune response using a sublingually administered formulation particularly, but not exclusively, for use in immunisation as a prophylactic or therapeutic vaccine, or in the treatment of allergy.

10 Background of the Invention

- The immune system has evolved specifically to detect and eliminate foreign or new material from a host. This material may be of viral, bacterial, or parasitic origin and may reside outside or within the cells of the host, or be of neoplastic origin. It may
15 also be from other sources and not pathogenic or not intrinsically damaging to all subjects.

- The mucosal immune system (MIS) consists of lymphoid tissues within and directly beneath the epithelial lining of the respiratory, genitourinary and gastrointestinal
20 tract as well as beneath the ductal system of the salivary, lacrimal and mammary glands. The primary product of the MIS is IgA.

- Vaccination is the best known and most successful application of an immunological principle to human health. Naturally, to be introduced and approved, a vaccine must
25 be effective and the efficacy of all vaccines is reviewed from time to time. Many factors affect the efficacy of a vaccine. For example, a vaccine is usually administered by the subcutaneous or intramuscular route. Recently the sublingual route has been used for administration of therapeutic allergy vaccines. An effective

vaccine must induce the appropriate immunity in terms of quantitative and qualitative effects and be stable on storage. With non-living vaccines in particular, it is often necessary to boost their immunogenicity with an adjuvant. This can also apply to some live, e.g. attenuated vaccines. An adjuvant is a substance that enhances the immune response to an antigen.

During work in the 1920s on the production of animal antiserum for human therapy, it was discovered that certain substances, notably aluminium salts added to antigens or emulsions incorporating antigen, greatly enhance antibody production, i.e. they act as adjuvants. Aluminium hydroxide is still widely used with, e.g. diphtheria and tetanus toxoid and insoluble tyrosine is used with some allergy vaccines. Other more soluble adjuvants also have desirable effects such as inducing a heightened immune response or driving the response towards for example a TH1 type response.

3 De-O-acylated monophosphoryl lipid A is known from GB-A-2220211 (Ribi). Chemically it can be a mixture of 3 de-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is now manufactured by Corixa Corporation. A preferred form of 3 de-O-acylated monophosphoryl lipid A (also referred to herein as MPL® adjuvant) is disclosed in International Patent Application No. WO92/16556.

International Patent Publication No. WO98/44947 described a formulation for use in desensitisation therapy of allergy sufferers which comprised an optionally modified allergen, tyrosine and 3 de-O-acylated monophosphoryl lipid A.

Considerable efforts have been made to produce better adjuvants, particularly for T-cell-mediated responses, but it should be stressed that few of these more recent adjuvants are yet accepted for routine human use. MPL® adjuvant, however, has

been licensed for use with a Melanoma vaccine and allergy vaccines containing MPL® adjuvant are available as 'Specials' in Germany, Italy and Spain.

WO00/50078 to Chiron describes a composition which includes bioadhesives in combination with adjuvants and antigens for mucosal delivery. However, it only demonstrates the production of an IgG immune response with the composition. Further, the bioadhesive is an agent which physically or chemically binds to mucus. It is believed that there may be safety concerns associated with such bioadhesion of some antigen-containing compositions. Sublingual delivery is not taught; the test composition being administered intranasally.

Clearly there is still a need for a composition that generates a mucosal and systemic immune response to protect against bacteria, viruses and other parasitic organisms, and that may be used as an allergy vaccine. Ideally such a composition should be administerable via a route which is associated with good patient compliance, such as the sublingual route. It has also been found that sublingual delivery may give rapid absorption and good bioavailability of the substance being delivered. Sublingual delivery may also be advantageous over intermittent injections in maintaining adequate blood concentrations of the substance being delivered. Preferably the composition should make use of conveniently available adjuvants.

Summary of the Invention

The present invention relates to a sublingual delivery system and has advantages associated with this means of delivery. In more detail, we have now found it possible to use glycolipid adjuvants, such as MPL® adjuvant, with an antigen to produce a mucosal immune response (MIR) when administered sublingually. We

- understand we are the first to realise that the use of glycolipid adjuvants sublingually can produce a systemic IgG as well as a mucosal IgA-mediated response. Surprisingly we have also found that the MIR may be generated at a site which is distal to, as well as local to, the sublingual site of delivery. For example, IgA may be
- 5 detected at other lymphoid tissues, such as in the intestinal tract, respiratory tract and genitourinary tract. This has particularly important implications for the treatment of, for example, sexually transmitted diseases, as sublingual application is convenient and may therefore lead to good patient compliance with any dosage regimen.
- 10 It appears that the effect of adjuvants is due mainly to two activities: the persistent concentration of antigen in a site where lymphocytes or other competent cells are exposed to it (the "depot" effect) and the induction of cytokines, which regulate lymphocyte function. Newer devices such as liposomes and immune-stimulating complexes (ISCOMS) may achieve the same purpose by ensuring that antigens
- 15 trapped in them are delivered to antigen-presenting cells. Bacterial products such as mycobacterial cell walls, endotoxin etc. are believed to act by stimulating the formation of cytokines. Cytokine induction may be particularly useful in immunocompromised patients, who often fail to respond to normal vaccines. It is hoped that such cytokine induction might also be useful in directing the immune
- 20 response in the desired direction, e.g. in diseases where only TH1 or TH2 cell responsiveness is wanted (Roitt *et al* "Immunology" 4th edition).

We also provide an antigen formulation, which can tilt the TH1-TH2 balance in favour of a TH1 response, which can be administered to the mucosae preferably to

25 the mouth and in particular to the sublingual site. The formulation is useful in immunotherapy, particularly in the field of vaccines. It is also useful in studying immune responses and in the production of antibodies.

Statement of Invention

In its broadest sense the present invention relates to the finding that glycolipids will drive a systemic and mucosal humoral response to antigen when a composition containing them is administered sublingually in a human or animal. We have found that any convenient sublingually administerable excipient may be employed. The ability of a glycolipid adjuvant to drive serum IgG, IgG₁ and IgG_{2a} when administered with antigen sublingually shows that the invention is applicable to prophylactic vaccines as well as allergy desensitisation. The ability of a glycolipid adjuvant to drive mucosal IgA after sublingual dosing additionally shows that the invention is a useful way to generate mucosal immunity. The generation of mucosal immunity is useful in protecting against airborne pathogens and sexually transmitted diseases in particular.

In general terms the present invention relates to a composition comprising (A) at least one antigen and (B) a glycolipid adjuvant and uses thereof.

In particular, according to one aspect of the present invention there is provided a method of producing a mucosal and/or systemic immune response in a human or animal in need of the same comprising administering a composition comprising at least one antigen and a glycolipid adjuvant.

Put another way the present invention relates to the use of at least one antigen and a glycolipid adjuvant in the preparation of a medicament for producing a mucosal and/or systemic immune response.

According to another aspect of the present invention there is provided a method of treating a mucosally transmitted disease comprising administering sublingually to a

human or animal a composition comprising at least one antigen and a glycolipid adjuvant.

Put another way the present invention relates to the use of at least one antigen and a glycolipid adjuvant in the preparation of a sublingually-administerable medicament for treating a mucosally transmitted disease.

These methods of the present invention generate an IgA-mediated immune response.

Thus, the present invention also provides a method of producing an IgA immune response in a human or animal comprising administering sublingually a composition comprising at least one antigen and a glycolipid adjuvant.

Put another way the present invention relates to the use of at least one antigen and a glycolipid adjuvant in the preparation of a sublingually-administerable medicament for producing an IgA immune response.

The composition should be administered in an effective amount. The term "effective amount" refers to a non-toxic but sufficient amount of the composition to provide the desired immunological response. An appropriate effective amount may be determined by one skilled in the art.

The compositions according to the invention may be either prophylactic (i.e. prevent infection) or therapeutic (to treat disease after infection).

Preferably the composition is administered to humans, mammals and other primates, including non-human primates such as apes and monkeys, farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats;

laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.

- 5 The method of the present invention may also generate an IgG-mediated immune response.

According to another aspect of the present invention there is provided a composition comprising:

- 10 (A) one or more antigens; and
(B) a glycolipid adjuvant.

In an especially preferred embodiment the glycolipid is a TH1-inducing adjuvant.

- 15 Preferably the composition useful in the present invention comprises a sublingually administerable diluent, excipient or carrier which aids availability of (A) and (B) at the site of administration (mucosal sublingual site).

- 20 Preferably the antigen is derived from a bacterium, virus, prion, neoplasm, autoantigen, plant, animal, or other pathogenic or non-pathogenic organism, synthetic or recombinant material.

The antigen may comprise selected portions of antigenic molecules, or molecules made by synthetic or recombinant technologies.

25

Preferably, the antigen is an allergen. Allergens are types of antigens, which have the propensity to induce allergy. The allergen may comprise selected portions of allergenic molecules, or molecules made by synthetic or recombinant technologies.

Hereafter the words antigen or antigens encompass the word allergen or allergens respectively.

Preferably the antigen is in the form of a polypeptide, carbohydrate or lipid.

- 5 Alternatively, the antigen may be in the form of a vector comprising a polynucleotide encoding an antigenic polypeptide, and where said polynucleotide is operably linked to a regulatory sequence which regulates expression of said polynucleotide.

- 10 Preferably the TH1-inducing adjuvant is but is not limited to MPL® adjuvant, 3D-MPL or a derivative or salt thereof, or is some other TH1-inducing adjuvant or combinations of such adjuvants.

Preferably the composition is in the form of a vaccine.

15

Preferably the composition is in the form of an aqueous solution, a gel, a patch, a lozenge, capsule or a tablet, most preferably an aqueous or gel solution.

- 20 The present invention also provides for use of the composition in the preparation of a medicine for treatment of or prevention of a bacterial, viral prion infection, or other disease such as cancer, autoimmunity or allergy in a human or animal.

- 25 The invention further provides for use of the composition in a method for producing one or more antibodies that recognise said antigen. The antibodies produced may be used in the manufacture of a medicament for treating bacterial or viral infection, cancer, autoimmunity or allergy in a human or animal. The present invention is particularly important in relation to airborne pathogens and sexually transmitted diseases.

The present invention further provides a method for preparing an antiserum or immunoglobulin preparation from it, comprising immunising a human or animal with a composition of the present invention.

5

The present invention also provides a method for preparing a composition of the present invention comprising mixing a solution of antigens and the glycolipid adjuvant with a pharmaceutically acceptable diluent, carrier or excipient, preferably an aqueous solution or a gel.

10

Detailed description

Various further preferred features and embodiments of the present invention will now be described by way of non-limiting example.

15

Immune response

An immune response is a selective response mounted by the immune system of vertebrates in which specific antibodies and/or cytotoxic cells are produced against invading microorganisms, parasites, transplanted tissue and many other substances which are recognised as foreign by the body, i.e. antigens. The production of antibodies circulating in the blood is known as a humoral response; the production of cytotoxic cells as a cell-mediated or cellular immune response.

25 The cells involved in the immune system are organised into tissues and organs in order to perform their functions most effectively. These structures are collectively referred to as the lymphoid system. The lymphoid system comprises lymphocytes, accessory cells (macrophages and antigen-presenting cells) and in some cases,

epithelial cells. It is arranged into either discretely capsulated organs or accumulations of diffuse lymphoid tissue. The major lymphoid organs and tissues are classified as either primary (central) or second (peripheral). The present invention focuses on the secondary lymphoid organs. Secondary lymphoid organs
5 include mucosa-associated tissues, and provide an environment in which lymphocytes can interact with each other, with accessory cells, and with antigens.

- In more detail, the generation of lymphocytes in primary lymphoid organs (lymphopoiesis) is followed by their migration into peripheral secondary tissues.
- 10 The secondary lymphoid tissues comprise well-organised encapsulated organs – the spleen and lymph node – and non-encapsulated accumulations that are found around the body. The bulk of the non-organised lymphoid tissue is found in associated with mucosal surfaces and is called mucosa-associated lymphoid tissue (MALT).
- 15 The muscosal system protects the organism from antigens entering the body directly through mucosal epithelial surfaces. Thus, lymphoid tissues are found associated with surfaces lining the intestinal tract, the respiratory tract and genitourinary tract. The present invention particularly relates to lymphoid tissues found associated with surfaces lining the sublingual region. The major effector mechanism at these sites is
20 secretory IgA (sIgA), secreted directly onto the mucosal epithelial surfaces or the tract.

Secretory IgA represents over 95% of all Ig found in secretions and is primarily dimeric with two monomeric units covalently joined by a J chain. Dimeric IgA
25 binds to a polymeric immunoglobulin receptor pIGR on the basal surface of mucosal epithelial cells. This IgA-pIGR complex is endocytosed and transported to the apical (luminal) surface of the epithelial cell. During this transport process, a small piece

of the pIGR is cleaved with the remaining component now called the secretory component. Thus, IgA is secreted as dimeric IgA bound to a secretory component.

5 Secretory IgA does not activate the complement system but coats bacteria and viruses such as polio, coxsackie, rota and herpes, thus preventing their adherence to mucosal lining epithelium. Also, some viruses within surface epithelia can be neutralised by pIGR-internalised IgA.

10 The generation of secretory IgA, and hence the generation of a mucosal immune response (hereinafter MIR), may be detected using techniques standard in the art, such as ELISA. By way of example only the standardised ovalbumin ELISA test used in Examples 1 and 2 is described in Preparation Example 1.

15 A MIR to an antigen may lead to a state of systemic response to the same antigen, known as mucosal or oral tolerance. Thus, mucosal immunisation is an effective way to stimulate both local and systemic immune responses.

Antigen

20 Historically, in the art, the term "antigen" was used for any molecule that induced B cells to produce a specific antibody. Now, however, the term may be used to indicate any molecule that can be specifically recognised by the adaptive elements of the immune response, i.e. by B cells or T cells, or both. Thus the term "antigen" is understood in the art to mean a molecule which reacts with preformed antibody
25 and/or with various specific receptors on T and B cells. This definition includes what are traditionally known as "allergens", i.e. an agent, e.g. pollen dust, that causes IgE-mediated hypersensitivity.

An allergy (type 1 hypersensitivity) is a response to environmental antigen (allergen) in which IgE antibody is produced in relatively large amounts in allergic subjects compared with a non allergic person and is attached to mast cells and basophils in particular. An immediate hypersensitivity reaction is produced by mast cell products (histamine, etc.) when they are released following the reaction between IgE on the mast cell or basophil surface and allergen causing asthma, hay fever, serum sickness, systematic anaphylaxis or contact dermatitis. There are four types of hypersensitivity reaction (Types I, II, III and IV). The Type II and III are antibody-mediated; the fourth is mediated mainly by T cells and macrophages. The invention allows one to immunise with an allergen in order to bias away from an allergic IgE immune response towards a non-allergic immune response.

Thus, the "antigen" used in the present invention may be an "allergen" derived from any allergy causing substance, such as pollen (e.g. ragweed or birch pollen), food, insect venom, mould, animal fur or house dust mite (*D. farinae* or *D. pteronyssinus*).

The antigen used in the present invention is preferably an immunogen, i.e. an antigen that activates immune cells to generate an immune response against itself.

In a preferred embodiment, the present invention relates to a formulation for use as a vaccine and the antigen is one useful in such a vaccine.

The antigen used in the present invention can be any appropriate antigen, which is or becomes available.

The type of antigen used in a vaccine depends on many factors. In general, the more antigens of a microbe retained in the vaccine the better and living organisms tend to be more effective than killed ones. Exceptions to this rule are diseases where a toxin

is responsible for any pathogenic effect. In this case the vaccine can be based on the toxin or toxoid alone.

The antigen used in the present invention may be derived from any living organisms; intact or non-living organisms; subcellular fragments; toxoids; recombinant DNA-based antigens or anti-idiotypes or synthetic antigens. The antigen may be derived from natural or attenuated organisms, which may be viral or bacterial. The type of antigen may be a capsular polysaccharide, surface or internal antigen. If recombinant DNA-based, the antigen may be obtained from a cloned and expressed gene or naked DNA.

The antigen may be modified by reaction for example with a cross-linking agent, such as a dialdehyde, more particularly glutaraldehyde.

For example micro-organisms against which vaccines are available or are sought include *Salmonella*, *Shigella*, *Klebsiella*, *Enterobacter*, *Serratia*, *Proteus*, *Yersinia*, *Vibrio*, *Aeromonas*, *Pasteurella*, *Pseudomonas*, *Acinetobacter*, *Moraxella*, *Flavobacterium*, *Bordetella*, *Actinobacillus*, *Neisseria*, *Brucella*, *Haemophilus* and *Escherichia coli*.

Preferred vaccines include vaccinia (for smallpox); vole bacillus (for TB); polio; measles, mumps; rubella; yellow fever; varicella-zoster; BCG; rabies; influenza; hepatitis A; typhus; pertussis; typhoid; cholera; plague; penumococcus; meningococcus; *Haemophilus influenzae*; hepatitis B; hepatitis C; tetanus and diphtheria. Toxin based vaccines include *Chlostridium tetani*, *Corynebacterium diphtheriae*, *Vibrio cholerae* and *Clostridium perfringens*.

Other major diseases for which vaccines may be useful include: HIV, herpes, viruses, adenoviruses, rhinoviruses, staphylococci, group A streptococci, *Mycobacterium leprae*, *Treponema pallidum*, *Chlamydia*, *Candida*, *Pneumocystis*, malaria, trypanosomiasis; Chagas' disease; schistosomiasis and onchocerciasis.

5

Sexually transmitted diseases for which vaccines may be useful include, in addition to HIV and herpes mentioned above: *Neisseria gonorrhoeae*, *Treponema pallidum*, *Trichomonas vaginalis*, *Haemophilus ducreyi*, *Chlamydia*, *Calymmatobacterium granulomatis* and hepatitis.

10

The presence of tumour antigens also has been demonstrated, and, as a result, the concept of vaccinating against cancer has arisen. Also, in principle, conception and implantation can be interrupted by inducing immunity against a wide range of pregnancy and other reproductive hormones.

15

Typically, the antigen will be a polypeptide, but alternative antigenic structures, such as nucleic acid, carbohydrates, lipids, whole or attenuated organisms, such as viruses, bacteria or protozoa may also be used.

20

The term "polypeptide" is used generally to denote molecules constructed of a plurality of amino acids, the amino acids being joined together covalently such as through peptide bonds. Generally, polypeptide is used interchangeably with "protein" or "peptide" in that no difference in size or function is implied. Recombinant polypeptides may be prepared by processes well known in the art such as those described in Sambrook *et al*, "Molecular Cloning: A Laboratory Manual"; 25 2nd Ed., Cold Spring Harbor Lab. Press (1989).

Glycolipid adjuvant

In general terms an adjuvant is a substance that non-specifically enhances the immune response to an antigen, i.e. is an immunostimulant. In general terms a glycolipid is a cell membrane lipid molecule with a carbohydrate chain attached to a hydrophobic tail. The preferred glycolipid adjuvants of the present invention are modified lipopolysaccharides. The lipopolysaccharide is modified such that its toxicity is reduced compared to the corresponding wild type lipopolysaccharide or lipopolysaccharide from which it has been derived. Preferably the glycolipid adjuvant used in the present invention is a detoxified enterobacterial lipopolysaccharide or its lipid A component. The term "detoxified" refers to both completely nontoxic and low residual toxic mutants of the toxin. Preferably, the detoxified adjuvant retains a toxicity of less than 0.01%, more preferably 0.001%, of the corresponding wild type toxin. Toxicity may be measured in CHO cells by evaluation of morphological changes.

Preferably the glycolipid adjuvant is a TH1-inducing adjuvant. By "TH1-inducing adjuvant" we mean an adjuvant, having properties that enhance the TH1 response to an antigen. However, such an adjuvant may also have the propensity to simply increase the level of antibody or antigen specific cells produced or even, by the induction of modulating cytokines cause anergy (non-responsiveness) in certain cell populations.

In more detail, the immune response to antigen is generally either T cell mediated (which may involve cell killing) or humoral (antibody production via recognition of epitopes on the antigen). The pattern of cytokine production by T cells involved in an immune response can influence which of these response types predominates: for example cell mediated immunity (TH1) is characterised by high IL-2 and IFN γ but

low IL-4 production, whereas in humoral immunity (TH2) the pattern can be low IL-2 and IFN γ but high IL-4, IL13, IL-5. Responses are usually modulated at the level of the secondary lymphoid organ or cells; so pharmacological manipulation of specific T cell and antigen presenting cell cytokine patterns can influence the type and extent of the immune response generated.

The TH1-TH2 balance refers to the interconversion or predominance of the two different forms of helper T cells. The two forms have large scale and often opposing effects on the immune system. If an immune response favours TH1 cells, then these cells will drive a cellular response with associated antibody production, whereas TH2 cells will drive an antibody-dominated response. The isotype of antibodies responsible for some allergic reactions, IgE, and associated inflammatory responses are induced by cytokines from TH2 cells.


The effectiveness of an adjuvant as a TH1-inducing adjuvant may be determined by determining the profile of antibodies directed against an antigen resulting from administration of this antigen in vaccines, which are also comprised of the various adjuvants.

Preferably the adjuvant is a modified lipopolysaccharide. As described in US Patent No. 4,912,094 enterobacterial lipopolysaccharides (LPS) is a powerful immunostimulant. However, it can also illicit harmful and sometimes fatal responses. It is now known that the endotoxic activities associated with LPS result from its lipid A component. Accordingly the present invention more preferably uses a detoxified derivative of lipid A. Corixa Corporation produced a derivative of lipid A originally known as refined detoxified endotoxin (RDE) but which has become known as monophosphoryl lipid A (MPL® adjuvant). MPL® adjuvant can be produced by refluxing LPS or lipid A obtained from heptoseless mutants of gram

- negative bacteria (e.g. *Salmonella* sp.) in mineral acid solutions of moderate strength (e.g. 0.1N HCl) for a period of around 30 minutes. This treatment results in loss of the phosphate moiety at position 1 of the reducing-end glucosamine. In addition the core carbohydrate can be removed from the 6' position of the non-reducing glucosamine during this treatment. MPL® adjuvant and 3-deacylated monophosphoryl lipid A and methods for their manufacture are disclosed in US Patent No. 4,436,727, and US Patent No. 4,912,094 and reexamination certificate B1 4,912,094.
- 10 Preferably, however, a modified LPS or lipid A is used in which the detoxified lipid A retains the core moiety attached to the 6' position of non-reducing glucosamine. Such derivatives of LPS and lipid A are also described in US Patent No. 4,912,094. In more detail, US Patent 4,912,094 discloses a modified lipopolysaccharide which is obtained by the method of selectively removing only the β -hydroxymyristic acyl residue of lipopolysaccharide that is ester-linked to the reducing-end glucosamine at position 3' of said lipopolysaccharide, which comprises subjecting said lipopolysaccharide to alkaline hydrolysis. Such de-O-acylated monophosphoryl lipid A (MPL® adjuvant), diphosphoryl lipid A (DPL) and LPS may be used in the present invention. Thus in a preferred embodiment, the present invention uses MPL® adjuvant, DPL or LPS in which the position 3' of the reducing end glucosamine is de-O-acylated. These compounds are known as 3D-MPL, 3D-DPL and 3D-LPS respectively.


In US Patent 4,987,237 derivatives of MPL® adjuvant having the formula:

18




are described, and wherein R^1 and R^2 are H, R^3 is straight or branched chain hydrocarbon composed of C, H and optionally O, N and S, which if more than one atom may be the same or different, wherein the total number of C atoms does not exceed 60, and the circle represents an MPL nucleus.

Alternatively the MPL® adjuvant derivative has the formula



wherein the segment of the derivative represented by



15

contains 2-60 C atoms and wherein R^3 is straight or branched chain hydrocarbon composed of C, H and optionally O, N and S, which if more than one atom may be the same or different, and x is a minimum of 1 and can be any whole number such that the total number of C atoms in all x segments does not exceed 60, and wherein

the chemical structure of each R^3 may be the same or different in each such segment and wherein the circle represents an MPL nucleus.

One commercially available adjuvant from Corixa Corporation includes 2%
5 Squalene, 0.2% Tween 80 and as well as the MPL® adjuvant

Another commercially available adjuvant is Detox® adjuvant (Corixa Corporation) which comprises MPL® adjuvant and mycobacteria cell wall skeleton.

10 All such derivatives or salts of LPS or lipid A which are or become available may be used in the present invention. Preferably derivatives and salts are ones which are pharmaceutically acceptable.

The TH1-inducing adjuvant can be mixed with the other components of the
15 composition immediately prior to administration. Alternatively it can be formulated together with the other components during manufacture of the product. Alternatively, it can be administered at a different time than the other components. Administration can be by a number of routes. Preferably the glycolipid adjuvant is administered in an amount from 1.0 mg to 250 mg, more preferably 25 mg to 50 mg.

20

Vaccines

One aspect of the present invention relates to a method for inducing an immunological response, preferably a mucosal immunological response, in a
25 mammal, preferably humans, which comprises sublingually inoculating an individual with the composition of the present invention to produce antibody, preferably IgA, and/or a T cell immune response. Preferably the response is adequate to protect said individual from infection, particularly bacterial or viral infection. Preferably the

response is adequate to protect said individual from disease, whether that disease is already established within the individual or not. Thus, the immunological response may be used therapeutically or prophylactically.

5 Vaccines may be prepared from the composition of the present invention. The preparation of vaccines containing an antigen as the active ingredient is known to one skilled in the art. Typically, such vaccines are prepared either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to administration may also be prepared. The preparation may also be in a gel,
10 emulsified, or the composition encapsulated in liposomes. Suitable excipients are, for example, water, ammonium phosphate, dextrose, glycerol, ethanol, or the like and combinations thereof.

Compositions include such normally employed excipients as, for example,
15 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%. Where the vaccine composition is lyophilised, the lyophilised material
20 may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer.

In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and/or further
25 adjuvants, which enhance the effectiveness of the vaccine.

The proportion of antigen and adjuvant can be varied over a broad range so long as both are present in effective amounts. Typically, the vaccines are formulated to

contain a final concentration of antigen in the range of 0.2µg/ml to 200µg/ml, preferably 5µg/ml to 50µg/ml, most preferably about 15µg/ml. The preferred formulation can be determined through known dose range protocol and reference is made to "Remington: The Science and Practice of Pharmacy", Mack Publishing
5 Company, 19th Edn, 1995.

After formulation, the vaccine may be incorporated into a container which can be sterile that may then be sealed and stored at low temperature, for example 4°C, or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.
10

The antigens used in the invention may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as
15 acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine and procaine.

20 The composition be presented as a tablet, capsule or other convenient formulation with the excipients required to make such a formulation.

Preparation of antibodies using the composition of the invention

25 Compositions according to the invention may be used directly as immunogens by the routes of administration described herein, without the use of further adjuvants to generate antisera, specific immunoglobulins or monoclonal antibodies. The

invention thus provides a method for inducing antigen specific immunoglobulin production comprising the steps of:

- a) Immunising an animal with a composition according to the present invention;
and
- 5 b) recovering immunoglobulin specific for a region of the antigen of the composition from the serum of the animal.
- c) Selecting monoclonal antibody producing clones of cells.

10 Techniques for generating antibodies are taught in Kohler and Milstein, Nature (1975) 256:495-497.

The animals used for antibody production may be any animals normally employed for the purpose, particularly mammals. Especially indicated are mice, rats, guinea pigs and rabbits. The animals will be treated with the formulations described herein.

15

More particularly, the formulation of the present invention comprising the antigen can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g., mouse, rabbit, goat, horse, etc.) is immunised. Serum from the immunised animal is collected and treated according to known procedures. If serum contains polyclonal antibodies to other antigens, the required polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.

20

Monoclonal antibodies directed against antigens used in the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B-lymphocytes with oncogenic DNA, or transfection with Epstein-

25

Barr virus. Panels of monoclonal antibodies produced against antigens can be screened for various properties; i.e., for isotype and epitope affinity.

5 An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementary determining regions (CDRs). This technique is well known in the art.

10 Antibodies, both monoclonal and polyclonal, which are directed against antigens are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotypic antibodies. Anti-idiotypic antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired.

15 Techniques for raising anti-idiotypic antibodies are known in the art. These anti-idiotypic antibodies may also be useful for treatment, as well as for an elucidation of the immunogenic regions of antigens.

20 For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies that retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab')₂ fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.

25 Preparation of Composition

The composition of the present invention may be prepared by mixing an aqueous solution of the antigen with the glycolipid adjuvant, and adding the mucosally

administerable diluent, excipient or carrier either before or after the aforementioned mixture. Alternatively the glycolipid adjuvant may be co-precipitated with the antigen. As well as being mixed or co-precipitated with the other components of the composition prior to administration, the glycolipid adjuvant can be administered at a
5 different site and/or time to the other components. The mixture of glycolipid adjuvant and antigen can also be incorporated in gels, capsules, lozenges etc. or can also be presented in various devices such patches which can be bi- or preferably uni-directional.

10 MPL (or other TH1-inducing adjuvant) which has been dissolved by sonification or other means (described later in **Preparation of a solution of MPL® adjuvant**), can be diluted by various means prior to its addition to antigens. The preparation of MPL is initially made at a concentration of typically between 0.5mg per ml and 4mg per ml, for example 1mg per ml. It can then be diluted to a concentration of between
15 500µg/ml and 20µg/ml, preferably 100µg/ml. This dilution can be made in pure water or in other solvents such as in an aqueous glycerol solution containing between 1% and 50% glycerol.

Suitable physiologically acceptable carriers and diluents include sterile water or 5%
20 dextrose water solution. The compositions are for human or veterinary use and are formulated for mucosal, preferably sublingual delivery.

The routes of administration and dosages described herein are intended only as a guide since a skilled practitioner will be able to determine readily the optimum
25 mucosal route of administration and dosage for any particular patient and condition.

Formulation, Dosage and Administration of Compositions

The composition of the present invention may conveniently be formulated with a pharmaceutically acceptable diluent, carrier or excipient suitable for sublingual administration. Details of pharmaceutical excipients may be found in "Handbook of Pharmaceutical Excipients", 2nd Ed. (1994), The Pharmaceutical Press, London,
5 Editors: Wade & Weller.

We have found that an important aspect of the present invention is sublingual administration of the composition of the present invention. A gel or other viscous formulation may be expected to be preferred due to increased antigen contact with
10 the sublingual surface. However, results may also be achieved with other formulations such as an aqueous solution. In mice, a simple solution was found to give similar results to a gel formulation. It is not required nor desirable that the formulation should physically or chemically bind to the mucosal tissue.

15 Formulations suitable for sublingual administration include aqueous and non-aqueous sterile solutions which may contain anti-oxidants, buffers, bacteristatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the mucus, of the individual; the aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The
20 formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

Preferably a carrier is also present in the composition according to the invention.
25 The carrier may be an oil in water emulsion, or an aluminium salt, such as aluminium phosphate or aluminium hydroxide.

Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g., squalane or squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

- 5 The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating cancers autoimmune diseases and related conditions.

10 In general, carriers may include, but are not limited to, dextrose, water, glycerol, ethanol and combinations thereof.

The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

15

Administration of these compositions may be in the form of salves, pastes, gels, solutions, powders and the like. Gels may conveniently be formulated using carbopol also known as carbomer – a carboxyvinyl polymer, or a cellulose-based thickening agent such as hydroxyethyl cellulose, hydroxypropyl cellulose or
20 hydroxypropyl methylcellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium, ethyl cellulose, methylcellulose. Gels may also be conveniently formulated using: acacia, alginic acid, bentonite, cetostearyl alcohol, gelatin, guar gum, magnesium aluminium silicate, maltodextrin, polyvinyl alcohol, propylene carbonate, propylene glycol alginate, colloidal silicon dioxide, sodium
25 alginate, tragacanth, and/or xanthan gum. Particularly preferred are carbopol and the cellulose-based agents.

- The compositions are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be administered, which is generally in the range of 0.5 μ g to 250 μ g of antigen per dose, depends on the subject to be treated, the capacity of the subject's immune system to synthesise antibodies, and the degree of protection desired. A preferable range is from about 2 μ g to about 40 μ g per dose. In some cases the patient will be treated with a series of administrations which will include a rising antigen dose regime.
- 10 A suitable dose size is about 0.1 ml, but within a regime this may start at a lower volume and finish at a higher volume. The precise amounts of active ingredient administered may depend on the judgement of the practitioner and may be peculiar to each individual subject.
- 15 The composition may be given in a single dose schedule, or preferably in a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1 to 4 months for a second dose, and if needed, a subsequent dose(s)
- 20 after several months. When the product is being used for the treatment of allergy the administration regimes will include more frequent dosing. The dosage regimen will also, at least in part, be determined by the needs of the individual and be dependent upon the judgement of the practitioner.
- 25 In addition, the composition containing the antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins.

The invention will be described with reference to the following examples that are intended to be illustrative only and not limiting.

Examples

5

Preparation of a solution of MPL® adjuvant

A 4 mg/ml solution of 1,2-dipalmitoyl-SN-glycero-3-phospho choline (DPPC) in absolute ethanol was prepared. For each 1.0 mg of MPL-TEA (triethylamine) salt to be solubilised, 27 µl of DPPC were added to dissolve the MPL. MPL may be prepared as described above. The ethanol was removed by blowing a stream of N₂ gently into the vial. Next 1.0 ml of pyrogen-free water for injection was added for each mg of MPL in the dried MPL/DPPC mixture. The solution was sonicated in a bath sonicator at 60-70°C until clear. The MPL/DPPC solution was then filter sterilised by filtration through a SFCA 290-4520 Nalgene 0.2 µm filter. The MPL/DPPC solution was aseptically dispensed at 1.0 mg/ml into depyrogenated vials, labelled MPL-AF (MPL solubilised in the surfactant DPPC), and stored at 4°C.

15

Formulation of Ovalbumin (XOA)/MPL® adjuvant/Sublingual Gel.

20

TH1 inducing activity in mice can be equated with the production of specific IgG2a and IgG2b antibodies and the TH2 inducing activity with the production of specific IgG1 antibodies and IgE antibodies. Specific secretory IgA antibodies can identify whether a mucosal response has occurred whether it be local (salivary antibody) or distal (vaginal antibody) following sublingual immunisation. The immunogenic potential of a formulation can be investigated, however, by measuring solely the specific IgG response in serum.

25

Therefore, as an example, an experiment was carried out in mice to demonstrate the profiles of the allergen specific antibodies to an exemplar, ovalbumen (XOA) which is accepted as a model antigen and is also a well-known allergen derived from chicken eggs.

5

Stock Materials.**1. Carbopol TR-1 NF stock (0.83%)**

- 10 A. 100mg carbopol TR-1 NF in 20ml WFI (water for injection) = 0.9% w/v gel.
- B. To A was added 0.8ml 10% v/v TEOA (triethanolamine) = 0.8% w/v gel.

15 11 **MPL AF glycerol (20mg/ml)**

- A. MPL 40mg
- DPPC 4.32mg
- Glycerol 800µl
- 20 WFI qs 40ml
- Sonicated to particle size approx. = 80nm

 B. Lyophilised

25 C. Reconstituted with 1.2ml WFI-20mg/ml MPL.

111 **Ovalbumin Stock (33mg/ml)**

30

Ovalbumin	33mg
WFI	1.0ml

Formulation For Injection

5

Carbopol stock	1920 μ l
Ovalbumin stock	480 μ l
Glycerol	480 μ l
WFI	720 μ l
MPL glycerol	400 μ l

10

1. Carbopol, XOA, glycerol and WFI were added into a 5ml vial and mixed by vortexing.
2. MPL glycerol was added to the above and further vortexing carried out.

15 Immunisation of mice

Groups of 5 eight-week-old female Balb/C mice were anaesthetised with Ketamine. When the mice were unconscious, 20 μ l of the appropriate gel containing various amounts of XOA was placed under the tongue for 5 minutes. The gels were rinsed out of the mouth after 5 minutes. With 1.0ml 0.9% saline using a syringe and a gavage needle.

20

Three weeks later the mice were treated identically to the first treatment.

The mice were bled 2 weeks after the second treatment and sera collected. These were assayed for XOA specific IgG antibodies using an ELISA assay.

Results

- Anti-Ovalbumin IgG Responses in Mice Administered Either 83.2 μ g or 3.4 μ g Ovalbumin and 33.6 μ g MPL in 20 μ l Carbopol Gel via the Sublingual Route, Boosted after 3 Weeks and Bled 2 Weeks later. (Average OD (optical density) Values of 5 Mice per Group).

OD Values at Different Serum Dilutions

	1/10	1/30	1/90	1/270	1/ 610
Group 1 Dose 83.2 μ g XOA	1.1	1.0	0.75	0.5	0.3
Group 2 Dose 3.4 μ g XOA	0.6	0.5	0.35	0.15	0.05
Group 3 Carbopol only	0.15	0.1	0.05	0.05	0.05

10

Example 2

Preparation of Materials for Immunisation of Mice

- 15 The immunising doses of XOA/MPL in carbopol or alternatively in the diluent (aqueous formulation) without MPL were prepared as described in Example 1 except for the use of different doses.

Immunisation of Mice

20

1. Each mouse was anaesthetized before administration

2. 20 μ l of the appropriate material was placed under the tongue for 5 minutes. Thus, each of the groups of mice was administered the following amounts of substances in 20 μ l.

5

Group	Antigen	MPL	Excipient
1	80 μ g ovalbumin	20 μ g MPL	Carbopol
2	80 μ g ovalbumin	0 μ gMPL	Carbopol
3	0 μ g ovalbumin	160 μ gMPL	Carbopol
4	80 μ g ovalbumin	40 μ gMPL	Diluent

3. The material was rinsed out of the mouth after 5 minutes with 1.0ml of 0.9% saline

10

4. Three weeks after the primary vaccination and again a further two weeks after this the mice were retreated

5. Mice were bled 2 weeks after the third application and the sera stored until use at -20C. Nasal and pulmonary washings were made and stored under the same conditions.

15

6. Sera and washings were tested for ovalbumin specific antibodies as previously.

20

RESULTS

Serum IgG antibodies specific for XOA Titre log(2)/ reference titre (log)2 (SD)

25

GROUP	Serum IgG1	Serum IgG2a	Serum IgG
1	0.625 (0.375)	0.35 (0.4)	0.6 (0.3)
2	0	0	0.2 (0.05)
3	0	0	0.25 (0.02)
4	0.95 (0.01)	0.85 (0.2)	1.0 (0.05)

Geometric mean Anti XOA IgA antibodies in different fluids (SD)

GROUP	SERUM	NASAL WASH	PULMONARY WASH
1	0	73.6 (154.2)	238.5 (533.4)
2	0	0	0
3	0	0	0
4	2,291.3 (2,577.1)	568.5 (395.4)	2,518.4 (3,403.1)

5

The strong serum IgG response to XOA requires the addition of MPL, which also appears to have stimulated a TH1 type response indicated by the IgG2a antibody response.

- 10 A novel and unexpected finding was the strong induction of an XOA-specific IgA response when MPL was used as an adjuvant.

- 15 In mice there was no apparent advantage of using carbopol as an excipient. In fact there was strong evidence that the aqueous formulation of XOA and MPL was more immunogenic for both IgG and IgA induction without carbopol. This included serum IgA, only seen in the absence of carbopol. However, it is necessary to use excipients in the formulation of vaccines and carbopol may be a useful and convenient excipient formulation for human or animal use.

Preparation Example 1 – OVALBUMIN ELISA

1. Sera (diluted 1:2 in borate buffer) from each of the five mice in each group are tested in an ELISA assay to determine the anti-ovalbumin IgG or IgA antibody titers.
5
2. To run the ELISA, the following equipment and supplies are required:
 - 10 A. Immulon 2 plate, 96 well, flat bottomed, DYNATECH LABORATORIES catalog #011-010-3455. Three plates per product lot tested (enough to test sera from 10 mice in duplicate).
 - B. Ovalbumin (chicken egg), Sigma Grade 5. Stock solution (1 mg/mL in Water for Injection) made fresh each time the assay is run
15
 - C. Clean (autoclaved) pipet tips
 - D. 20, 100, 200, 1000 μ l pipettors
20
 - E. 8 channel pipettor; 200 μ l size
 - F. Clean (new) 13 mm test tubes or 2 mL cryovials and rack
 - 25 G. Parafilm or Saran Wrap
 - H. 1N H_2SO_4

- I. Horse radish peroxidase-labeled anti-IgG or anti-IgA secondary antibody (Used at 1:5,000). Southern Biotechnology Associates, Inc.
- 5 J. OPD kit: o-Phenylenediamine tablets, one per plate and diluent. Abbott Labs' *in vitro* Test No. 7181E. Often available in house.
- K. Mouse sera to be tested. Sera should have been diluted 1:2 in Borate Buffer for long-term storage.
- 10 L. Borate Buffer (BB):
Dissolve the following in 4 L sterile WFI:
12.4 g Boric Acid, Fisher Scientific #A73-500
0.764 g Sodium Borate (Borax), Fisher Scientific #S248-500
15 17.53 g Sodium Chloride, Fisher Scientific #S271-500
Store at room temperature, expires in six months
- M. Borate Buffer + 0.1% Tween 20 (BB-T20):
Add 1 mL Tween-20 (Sigma #P-1379) to 1 liter BB, mix thoroughly.
20 Store at room temperature, expires in six months.
- N. Borate Buffer-Tween-20-1% BSA (BB-BSA):
Dissolve 1.90 g EDTA (tetrasodium, Fisher Scientific #BP 121-500)
and 10 g BSA (Fraction V, protease-free, Boehringer Mannheim
25 #100-350) in 1 liter BB-T20.
- O. 0.05 M Carbonate/bicarbonate buffer solution:

36

Dissolve 4.2 g of NaHCO_3 and 5.3 g of Na_2CO_3 in 1 liter of RO water or sterile Water for Irrigation and adjust the pH to 9.6. Store at 4°C , expires in three months. Warm to room temperature before use.

- 5 P. Automatic pipettor
- Q. Vortex mixer
- R. Microcentrifuge racks
- 10 S. Plate reader, capable of taking O.D. readings at 490 nm
- T. Incubator set at 37°C
- 15 U. 25 mL serological pipettes (Fisher Scientific)
- V. 15 mL polypropylene conical tubes (Fisher Scientific)
- W. Reagent basins for multichannel pipettor
- 20 X. Automatic plate washer
3. Procedure for running the ELISA
- 25 A. BINDING OF THE TEST ANTIGEN
- I. Antigen concentration for binding plates used in the adjuvant assay is
 50 $\mu\text{g/ml}$:

37

2.5 mL of the stock 1 mg/mL ovalbumin solution is added to 47.5 mL of 0.05 M carbonate/bicarbonate solution. This amount is enough to coat four 96 well plates at 100 μ L per well.

- 5 II. Plate is then covered with Saran Wrap and left level and undisturbed at 4°C in the dark overnight.

- 10 B. SERUM DILUTIONS: Briefly vortex each serum sample prior to dilution and each diluted sample prior to addition to the plate. A new pipet tip should be used to remove serum from the stock tubes when making the dilutions.

- I. The starting dilution for sera obtained from mice immunized with adjuvant and ovalbumin is 1:6.

- 15 C. BLOCKING THE PLATE

- I. When all sera samples are diluted, prepare the plate by vigorously shaking the coating buffer into a sink.

- 20 II. Rap the plate sharply on a paper towel pad to remove excess solution. Wash the plate three times with BB-T20 wash solution using the automatic plate washer programmed to wash with 350 μ L and to wait 5 seconds between each wash.

- 25 III. Using the multichannel pipettor, add 250 μ L BB-BSA per well. Cover and seal with saran wrap and incubate at 37°C for 30 minutes.

D. LOADING THE PLATE

- 5 I. Vigorously shake the blocking buffer into a sink and rap the plate sharply on a paper towel pad to remove excess solution.
- 10 II. Add 100 μ l BB-BSA to all wells on each plate. Add 100 μ l of the appropriately diluted serum samples to the appropriate wells in column #1. Each serum sample should be tested in duplicate.
- 15 III. Using the multichannel pipettor, pipet 100 μ l up and down eight times in column #1 to mix the sample, and then transfer 100 μ l to column #2. Again, pipet up and down eight times to mix and transfer 100 μ l to column #3. Repeat the serial dilutions through column #12. Discard the 100 μ l in the tips after column 12 is mixed. There should now be 100 μ l in each well of the plate.

E. INCUBATION

- 20 Cover and seal the plates with Saran Wrap or Parafilm. Incubate the plates for 1 hour at 37°C. Remove the unbound antibody by the procedure outlined in step 3a, again washing the plate three times with BB-T20.

F. CONJUGATE

- 25 I. Prepare the peroxidase-labeled anti IgG secondary antibody conjugate by diluting it 1:5,000 in BB-BSA (10 μ l antibody in 50 mL BB-BSA in a 50 mL conical tube). Invert the tube > 20 times and vortex for 30

39

seconds to thoroughly mix. Pour the diluted antibody into a clean reagent basin. Anti IgA conjugate may be prepared in a corresponding manner.

- 5 II. Add 100 μ l of conjugate solution to each well of the plate, including blank wells.
- III. Cover and incubate plate for 1 hour at 37°C.
- 10 IV. Remove the conjugate solution and wash plate three times as in step 3a.

G. COLOR DEVELOPING:

- 15 I. Prepare the substrate/colorimetric reagent 10-15 minutes prior to use (to give it time to dissolve completely) by dissolving 3 optical density developing tablets in 30.4 mL Substrate Buffer in a foil-covered 50 mL polypropylene conical tube.
- 20 II. Using the multichannel pipettor, add 100 μ l of reagent to each well. Incubate at room temperature for 15 minutes.
- III. Stop the reaction after 15 minutes by adding 50 μ l of 1M sulfuric acid to each well with the multichannel pipettor.

25

H. READING THE PLATE

40

- I. The plates should be "stopped" in a sequential fashion, with 1-2 minutes between each plate, so that the time from "stop" to "read" is consistent between plates (after stopping the reaction on the last plate, read the first plate on the appropriate plate reader at 490 nm. Read the second plate 1-2 minutes later, and the third plate 1-2 minutes after that).

I. DETERMINATION OF IMMUNOGLOBULIN TITRE

The titer of each of the sera samples is defined as the reciprocal of the first serial two-fold dilution that has an OD value that is greater than or equal to twice the background value. The OD values for the control animals are averaged at each dilution and the mean titer for the group is determined.

References referred to hereinbefore are incorporated by reference.

CLAIMS

1. A method of producing a mucosal and systemic immune response in a human or animal comprising administering sublingually an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said human or animal.
2. A method of treating a mucosally transmitted disease comprising administering sublingually to a human or animal an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant.
3. A method according to claim 1 or 2 wherein the method produces an IgA immune response.
4. A method of producing an IgA immune response in a human or animal comprising administering sublingually an effective amount of a composition comprising at least one antigen and a glycolipid adjuvant.
5. A method according to any preceding claim wherein the method also produces an IgG immune response.
6. A method according to any preceding claim wherein the composition additionally comprises a sublingually administerable diluent, excipient or carrier.
7. A method according to any preceding claim wherein the glycolipid adjuvant is a TH1-inducing adjuvant.

8. A method according to any preceding claim wherein the antigen is an allergen.

9. A method according to any preceding claim wherein the antigen is derived
5 from a bacterium, virus, prion, neoplasm, autoantigen, animal, plant, recombinant or synthetic material.

10. A method according to any preceding claim wherein the antigen is in the form of a polypeptide.

10

11. A method according to any preceding claim wherein the antigen is in the form of a vector comprising a polynucleotide encoding an antigenic polypeptide, and where said polynucleotide is operably linked to a regulatory sequence which regulates expression of said polynucleotide.

15

12. A method according to any preceding claim, wherein the glycolipid adjuvant is selected from MPL® adjuvant, 3D-MPL, or a derivative or salt thereof.

13. A method according to any preceding claim wherein the composition is in the
20 form of an aqueous solution, a gel, a capsule, a lozenge or a tablet.

14. A composition comprising:

- (A) one or more antigens;
- (B) a glycolipid adjuvant; and
- 25 (C) a sublingually administerable diluent, excipient or carrier.

15. A composition according to claim 14 wherein the glycolipid is a TH1-inducing adjuvant.

16. A composition according to claim 14 or claim 15 wherein the antigen is an allergen.
- 5 17. A composition according to any one of claims 14 to 16 wherein the antigen is derived from a bacterium, virus, prion, neoplasm, autoantigen, animal, plant, recombinant or synthetic material.
18. A composition according to any one of claims 14 to 17 wherein the antigen is
10 in the form of a polypeptide.
19. A composition according to any one of claims 14 to 17 wherein the antigen is in the form of a vector comprising a polynucleotide encoding an antigenic polypeptide, and where said polynucleotide is operably linked to a regulatory
15 sequence which regulates expression of said polynucleotide.
20. A composition according to any one of claims 14 to 19, wherein the adjuvant is selected from MPL® adjuvant, 3D-MPL, or a derivative or salt thereof.
- 20 21. A composition according to any preceding claim which is in the form of an aqueous solution, a gel, a lozenge, a capsule or a tablet.
22. A composition according to any one of claims 14 to 21 for use in the method
25 of any one of claims 1 to 13.
23. A pharmaceutical composition comprising the composition according to any one of claims 14 to 22 and a pharmaceutically acceptable diluent, excipient or carrier.

24. Use of a composition according to any one of claims 14 to 22 in the preparation of a medicament for treating or preventing or reducing the susceptibility to bacterial, viral prion infection or autoimmunity, cancer or allergy in a human or
5 animal.
25. Use of a composition according to any one of claims 14 to 22 in a method for producing one or more antibodies that recognise said antigen.
- 10 26. Use according to claim 25 wherein the antibody is IgA.
27. Use according to claim 25 wherein the antibody is IgG.
28. Use of an antibody produced according to any one of claims 25 to 27 in the
15 manufacture of a medicament for treating bacterial or viral infection, cancer, autoimmunity or allergy in a human or animal.
29. A method for preparing a composition according to any one of claims 14 to 22 comprising mixing a solution of an antigen, glycolipid adjuvant and a
20 sublingually administerable diluent, excipient or carrier.
30. A method according to claim 1 or claim 29 substantially as hereinbefore described with reference to the accompanying Examples.
- 25 31. A composition according to claim 14 substantially as hereinbefore described with reference to the accompanying Examples.

32. Use substantially as hereinbefore described with reference to the accompanying Examples.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 01/00142

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/39 A61K39/395 A61K39/35 A61K39/00 A61K39/02
A61K39/12 A61K31/7088 C12N15/63 A61P31/00 A61P35/00
A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, CHEM ABS Data, LIFESCIENCES

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 27636 A (AMERICAN CYANAMID CO ;HANCOCK GERALD E (US); SPEELMAN DAN J (US);) 8 December 1994 (1994-12-08) page 8-9 page 26 --- -/-	1-6,9, 10, 12-14, 17,18, 20-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

11 April 2001

Date of mailing of the international search report

03.05.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Wagner, R

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 01/00142

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SASAKI S ET AL: "Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a dna-monophosphoryl lipid A adjuvant vaccine" INFECTION AND IMMUNITY, US AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, vol. 66, no. 2, February 1998 (1998-02), pages 823-826, XP002128173 ISSN: 0019-9567 abstract page 825	1-7, 9, 11-17, 19-24, 29
X	US 5 762 943 A (DOLOVICH JERRY ET AL) 9 June 1998 (1998-06-09) abstract column 5 -column 6; example 1	1, 6, 8, 10, 12-14, 16, 18, 20-23, 29
X	US 5 776 468 A (HAUSER PIERRE ET AL) 7 July 1998 (1998-07-07) column 3 -column 4 column 15 -column 17	1, 2, 5-7, 9, 10, 12-15, 17, 18, 20-24, 29
X	WO 96 25664 A (IMMUNOTHERAPY INC ; YEDA RESEARCH AND DEV CORP LTD (IL); EISENTHAL) 22 August 1996 (1996-08-22) page 20 -page 23	1, 2, 6, 9, 12-14, 17, 20-24, 29
X	WO 95 17209 A (SMITHKLINE BEECHAM BIOLOG ; MOMIN PATRICIA MARIE (BE); GARCON NATHA) 29 June 1995 (1995-06-29) page 9; claims 1, 6; example 1	1, 2, 5-7, 9, 10, 12, 14, 15, 17-20, 22-24, 29
X	WO 98 43670 A (RIBI IMMUNOCHEM RESEARCH INC) 8 October 1998 (1998-10-08) abstract page 11; examples 4-7	1-7, 9, 10, 12-15, 17, 18, 20-27, 29
X	WO 95 05850 A (ENTERIC RES LAB INC) 2 March 1995 (1995-03-02) page 24 -page 26; claim 18	1, 2, 6, 9, 10, 14, 17, 21-24, 29
	-/-	

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/GB 01/00142

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 24577 A (STATENS SERUMINSTITUT ;ANDERSEN PETER (DK); SKJOET RIKKE (DK)) 20 May 1999 (1999-05-20) page 28 -page 31 page 34; claims 1,27 ---	1,2,6, 9-11,13, 14, 17-19, 21-24
X	WO 99 64074 A (CHATTERGOON MICHAEL A ;UNIV PENNSYLVANIA (US); BOYER JEAN D (US);) 16 December 1999 (1999-12-16) page 11 -page 16 page 24 ---	1,6,8,9, 11,13, 14, 16-19, 21-24,29
P,X	WO 00 62801 A (SMITHKLINE BEECHAM BIOLOG ;DESCHAMPS MARGUERITE (BE); LAFERRIERE C) 26 October 2000 (2000-10-26) page 25 page 16 ---	1,14
P,X	WO 00 29582 A (HELLSTROM KARL ERIK ;SCHOLLER NATHALIE B (US); DISIS MARY L (US);) 25 May 2000 (2000-05-25) page 44 -page 45; example 1 ---	1,5-7, 11,14, 15,17, 19, 22-24,29
P,X	WO 00 65058 A (KLYSNER STEEN ;M & E BIOTECH AS (DK)) 2 November 2000 (2000-11-02) page 35 -page 37 ---	1,14
P,X	WO 00 72876 A (SCHENK DALE B ;NEURALAB LTD (US)) 7 December 2000 (2000-12-07) page 11 page 53 ---	1,14
P,X	WO 00 78353 A (CORIXA CORP) 28 December 2000 (2000-12-28) page 4 -page 7 ---	1,14
P,X	EP 1 031 347 A (IDEA AG) 30 August 2000 (2000-08-30) page 5 page 15 ---	1,14
P,X	WO 00 50078 A (CHIRON CORP ;HAGAN DEREK O (US); SINGH MANMOHAN (US)) 31 August 2000 (2000-08-31) page 7 page 22 ---	1,14

-/-

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 01/00142

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SCHNEERSON R ET AL: "EVALUATION OF MONOPHOSPHORYL LIPID A MPL AS AN ADJUVANT ENHANCEMENT OF THE SERUM ANTIBODY RESPONSE IN MICE TO POLYSACCHARIDE-PROTEIN CONJUGATES BY CONCURRENT INJECTION WITH MPL"</p> <p>JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 147, no. 7, 1991, pages 2136-2140, XP002149961</p> <p>ISSN: 0022-1767</p> <p>the whole document</p> <p>-----</p>	1-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

Additional Application No

PCT/GB 01/00142

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9427636 A	08-12-1994	AT 196737 T	15-10-2000
		AU 676340 B	06-03-1997
		AU 6957194 A	20-12-1994
		BR 1100802 A	01-08-2000
		DE 69426077 D	09-11-2000
		DK 705109 T	13-11-2000
		EP 0705109 A	10-04-1996
		ES 2150493 T	01-12-2000
		FI 955667 A	12-01-1996
		JP 8510749 T	12-11-1996
		NO 954786 A	23-01-1996
		PT 705109 T	28-02-2001
		US 5723130 A	03-03-1998
US 5762943 A	09-06-1998	AU 3121497 A	05-12-1997
		CA 2252604 A	20-11-1997
		EP 0914114 A	12-05-1999
		JP 2000510844 T	22-08-2000
		WO 9742947 A	20-11-1997
US 5776468 A	07-07-1998	AU 685443 B	22-01-1998
		AU 6426494 A	11-10-1994
		BR 9405957 A	12-12-1995
		DE 69405551 D	16-10-1997
		DE 69405551 T	26-03-1998
		EP 0689454 A	03-01-1996
		FI 954514 A	22-09-1995
		GR 3025483 T	27-02-1998
		JP 8508722 T	17-09-1996
		NO 953759 A	22-09-1995
		PL 310598 A	27-12-1995
		SK 117395 A	06-11-1996
		AP 515 A	09-08-1996
		AT 157882 T	15-09-1997
		AU 705739 B	03-06-1999
		AU 7541696 A	13-02-1997
		CA 2157376 A	29-09-1994
		CN 1119829 A	03-04-1996
		CZ 9502467 A	13-03-1996
		DK 689454 T	08-12-1997
		WO 9421292 A	29-09-1994
		EP 0812593 A	17-12-1997
		ES 2109685 T	16-01-1998
		HU 72916 A	28-06-1996
		IL 109056 A	15-06-1998
		NZ 263538 A	28-10-1996
		SG 48309 A	17-04-1998
		ZA 9401957 A	31-01-1995
WO 9625664 A	22-08-1996	AU 4977896 A	04-09-1996
WO 9517209 A	29-06-1995	AT 177322 T	15-03-1999
		AU 1316495 A	10-07-1995
		AU 687494 B	26-02-1998
		AU 1316695 A	10-07-1995
		AU 705521 B	27-05-1999
		AU 6803198 A	09-07-1998
		AU 705519 B	27-05-1999

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 01/00142

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☒ Claims Nos.: 30-32
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 30-32

Claims 30-32 are not clear (Article 5 PCT) because they do not contain any technical feature

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/00142

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9517209 A		AU 6803298 A	09-07-1998
		CA 2179779 A	29-06-1995
		CN 1138298 A	18-12-1996
		DE 69417063 D	15-04-1999
		DE 69417063 T	28-10-1999
		DK 735898 T	23-08-1999
		WO 9517210 A	29-06-1995
		EP 0735898 A	09-10-1996
		EP 0868918 A	07-10-1998
		ES 2129801 T	16-06-1999
		GR 3029750 T	30-06-1999
		HK 1012243 A	12-05-2000
		JP 9506887 T	08-07-1997
		NZ 277802 A	27-04-1998
		SG 49257 A	18-05-1998
		SG 73578 A	20-06-2000
		SI 735898 T	30-06-1999
		US 6146632 A	14-11-2000
		ZA 9410176 A	17-11-1995
WO 9843670 A	08-10-1998	AU 6947398 A	22-10-1998
		BR 9811262 A	17-10-2000
		CN 1259052 T	05-07-2000
		EP 0971739 A	19-01-2000
		HU 0001403 A	28-09-2000
		NO 994760 A	26-11-1999
		PL 336698 A	03-07-2000
		TR 9902437 T	21-01-2000
WO 9505850 A	02-03-1995	AU 7482694 A	21-03-1995
		CA 2167691 A	02-03-1995
		EP 0719155 A	03-07-1996
		JP 9502604 T	18-03-1997
		US 5874300 A	23-02-1999
WO 9924577 A	20-05-1999	AU 6820498 A	22-10-1998
		AU 9433898 A	31-05-1999
		WO 9844119 A	08-10-1998
		EP 0972045 A	19-01-2000
		EP 1029053 A	23-08-2000
WO 9964074 A	16-12-1999	AU 4563099 A	30-12-1999
WO 0062801 A	26-10-2000	AU 3291900 A	09-10-2000
		AU 3430700 A	09-10-2000
		AU 3813600 A	09-10-2000
		AU 4552500 A	02-11-2000
		AU 5523300 A	02-11-2000
		WO 0056358 A	28-09-2000
		WO 0056359 A	28-09-2000
		WO 0056360 A	28-09-2000
		WO 0062802 A	26-10-2000
WO 0029582 A	25-05-2000	AU 3101500 A	05-06-2000
WO 0065058 A	02-11-2000	AU 4100800 A	10-11-2000
WO 0072876 A	07-12-2000	NONE	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 01/00142

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0078353 A	28-12-2000	NONE	
EP 1031347 A	30-08-2000	AU 2293400 A WO 0044350 A	18-08-2000 03-08-2000
WO 0050078 A	31-08-2000	AU 4673099 A	14-09-2000